Organon & Company
OGN
ISIN null / Valor 111523364
Organon & Company
UMushroom community rating:
About company
Organon & Company is a global healthcare company with a diverse portfolio of therapies and products focused on women's health, biosimilars, and established brands covering various conditions and diseases. Their established brands include treatments for cardiovascular disease, respiratory conditions, dermatology, central nervous system disorders, bone health, immunology, non-opioid pain management, menopause, and more. With a portfolio of over 60 medicines and products, Organon operates in more than 140 markets worldwide, offering important therapies in areas such as reproductive health, heart disease, oncology, immunology, dermatology, allergy, and asthma.
Summarized from source with an LLMView SourceSector: IndustrialsLatest Results (22.11.2025):
Organon & Company (Organon, NYSE: OGN) reported results for the second quarter of 2025: total revenue of $1.594 billion, GAAP diluted EPS of $0.56 ($0.14 per share of that reflects a $46 million gain on early extinguishment of debt) and non‑GAAP adjusted diluted EPS of $1.00; net income was $145 million and Adjusted EBITDA (non‑GAAP) was $522 million (32.7% margin). The company reduced debt and raised full‑year revenue guidance while affirming its Adjusted EBITDA margin range.
Top‑line and segment performance
Q2 2025 revenue $1.594B, down 1% year‑over‑year (also -1% ex‑FX). By segment: Women’s Health $462M (+3% reported, +2% ex‑FX), Biosimilars $173M (+5% reported, +6% ex‑FX), Established Brands $936M (‑3% reported, ‑4% ex‑FX), Other $23M (‑25% reported). Fertility and Hadlima drove growth; Atozet LOE in Europe and lower Singulair sales weighed on Established Brands.
Profitability and margins
GAAP gross margin 54.8% in Q2 (down from 58.4% a year ago) and non‑GAAP adjusted gross margin 61.7% (vs 62.0% prior year). Adjusted EBITDA was $522M with a 32.7% margin (improved from 31.9%), helped by a 3% reduction in operating expenses.
Earnings per share and net income
Net income $145M in Q2 2025 (‑26% vs Q2 2024); GAAP diluted EPS $0.56 (includes $0.14 from a $46M gain on early debt extinguishment). Non‑GAAP adjusted net income $261M and adjusted diluted EPS $1.00 (‑11% vs prior year adjusted EPS of $1.12).
Balance sheet, debt reduction and capital actions
As of June 30, 2025: cash & equivalents $599M, total debt $8.90B. During Q2 the company repaid $345M of long‑term debt, repurchased/cancelled $242M of 2031 notes (pre‑tax gain $42M) and terminated a Dermavant funding agreement (payment $103M, pre‑tax gain $4M). Management targets net debt/Adjusted EBITDA <4.0x by YE 2025 and aims for ≤3.5x by end of 2026.
Guidance and outlook
Organon raised full‑year 2025 revenue guidance to $6.275B–$6.375B (previously $6.125B–$6.325B) and affirmed non‑GAAP Adjusted EBITDA margin guidance at 31.0%–32.0%. The FX translation headwind is now expected to be ~ $50M (improved from ~ $200M previously).
Capital return
The Board declared a quarterly dividend of $0.02 per share, payable September 11, 2025 to holders of record as of August 15, 2025.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1776 M
Market cap (USD)
7,281,074
Daily traded volume (Shares)
14.96 / 14.61
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
